Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
8.57 ^USD	+1.06%		0.00%	+1.54%

May. 14	Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating	MT
May. 13	Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024

Voyager Therapeutics, Inc. Announces Names of Directors Not Standing for Re-Election

April 27, 2023 at 08:00 am EDT

Voyager Therapeutics, Inc. announced that Grace E. Col n, Ph.D., Catherine J. Mackey, Ph.D., Glenn Pierce, M.D., Ph.D., Michael Higgins,Jude Onyia, Ph.D, and Nancy Vitale will not stand for re-election as directors, at its Annual Meeting is to be held on June 6, 2023.

Latest news about Voyager Therapeutics, Inc.

Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating	May. 14	MT
Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Voyager Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER??-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting	May. 08	CI
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	Apr. 02	CI
Voyager Therapeutics, Inc. Announces CFO Changes	Apr. 02	CI
Guggenheim Initiates Voyager Therapeutics With Buy Rating, $22 Price Target	Mar. 26	MT
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target	Mar. 19	MT
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer	Mar. 13	MT
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024	Mar. 13	CI
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target	Mar. 07	MT
Transcript : Voyager Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Feb. 26	CI
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research	Feb. 20	CI
Certain Restricted Stock Units of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.	Feb. 17	CI
Certain Stock Options of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.	Feb. 17	CI
Certain Common Stock of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.	Feb. 17	CI
Transcript : Voyager Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Wedbush Trims Voyager Therapeutics' Price Target to $10 From $11, Neutral Rating Kept	Jan. 05	MT
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health...	Jan. 05
US job data raises doubts about the Fed's next moves	Jan. 05
Top Premarket Decliners	Jan. 05	MT

Chart Voyager Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Voyager Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.57 USD

Average target price

17.56 USD

Spread / Average Target

+104.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOYAGER THERAPEUTICS, INC.	+1.54%	461M
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research